PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 75084

Title: Pulmonary Complications of Portal Hypertension: The Overlooked Decompensation

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05348255

Position: Peer Reviewer

Academic degree: MD

Professional title: Professor

Reviewer’s Country/Territory: Egypt

Author’s Country/Territory: Romania

Manuscript submission date: 2022-01-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-16 13:45

Reviewer performed review: 2022-01-21 07:59

Review time: 4 Days and 18 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ ] Grade A: Priority publishing</th>
<th>[Y] Grade B: Minor language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[Y] Accept (General priority)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
</tr>
<tr>
<td></td>
<td>[ ] Rejection</td>
<td></td>
</tr>
</tbody>
</table>

| Re-review          | [Y] Yes                   | [ ] No                      |
SPECIFIC COMMENTS TO AUTHORS
None
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 75084

Title: Pulmonary Complications of Portal Hypertension: The Overlooked Decompensation

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 03198793

Position: Editorial Board

Academic degree: MD, PhD

Professional title: Chief Physician, Dean, Professor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Romania

Manuscript submission date: 2022-01-16

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-01-18 10:27

Reviewer performed review: 2022-01-22 15:28

Review time: 4 Days and 5 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

This minireview discussed three main pulmonary complications related to liver cirrhosis such as hepato-pulmonary syndrome, porto-pulmonary hypertension, and hepatic hydrothorax in a structured manner, which is valuable for clinical practice. However, there are some comments as follows:  

1. In the minireview, the description structure of the three complications was different. As for Hepatopulmonary Syndrome, the author did not provide the treatment strategies, while for Hepatic Hydrothorax, Context and a brief history is not included. In Porto-pulmonary hypertension section, some treatments were discussed in Context and a brief history.  

2. In the section of The un/mistreated complication, the authors introduce some studies on the treatment of portal pulmonary hypertension. I wonder why the title of this section is The un/mistreated complication.
PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases
Manuscript NO: 75084
Title: Pulmonary Complications of Portal Hypertension: The Overlooked Decompensation
Provenance and peer review: Invited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 06151796
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer’s Country/Territory: China
Author’s Country/Territory: Romania
Manuscript submission date: 2022-01-16
Reviewer chosen by: AI Technique
Reviewer accepted review: 2022-01-17 02:56
Reviewer performed review: 2022-01-26 10:17
Review time: 9 Days and 7 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[Y] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[Y] Accept (High priority)</td>
<td>[ ] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>[Y] Yes</td>
<td>[ ] No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
Generally speaking, this review has clearly described several main aspects of three overlooked pulmonary complications of portal hypertension, including the definition, diagnostic criteria, history and the challenges in measurement and treatment. Which mentioned in this review can help clinicians more clearly recognized these complications which associated with a worse outcome and taken earlier treatments to improve the prognosis if possible, especially in non-LT centers. I think this review is well-written and can help us in the clinical practice and potential researches. Certainly, I think it has met the criteria for publication. Other issues: 1. Dose the abbreviation ACLF means “Acute-on-chronic liver failure”? please make it clear. 2. Please note the references when citing specific data, such as in the “The (non)diagnostic challenge” part, paragraph 2.